5月22日，剂泰科技-P盘中下跌5.13%，报15.55港元，成交额1491.34万港元。该股自5月13日上市首日大涨173%后已连续多个交易日回调，较首日高点回撤显著。
消息面上，剂泰科技作为全球AI药物递送第一股于5月13日登陆港交所，IPO发售价10.50港元。公司尚处于商业化早期阶段，过去三年累计亏损约15亿元人民币，营收波动较大，业绩增长前景仍需时间验证。此外，部分国际配售股份未设置禁售期，上市后持续面临获利了结压力。随着新股上市初期市场热度加速消退，股价承压回落态势延续。
公司简介：剂泰科技是一家AI驱动纳米材料创新的生物科技公司，专注于靶向药物递送和发现技术，已自主开发AI纳米基座大模型及AiLNP、AiRNA、AiTEM三大核心平台，具备肝脏、肺部、肌肉和免疫细胞等关键组织的LNP精准靶向递送能力。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.